Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Avastin for neovascular age-related macular degeneration
2006-004320-36Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Prevention of visual acuity loss. Started May 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2006-004320-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004320-36.